A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ADJUVANT
- 26 Jan 2018 Planned number of patients changed from 1100 to 1360.
- 26 Jan 2018 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2023.
- 10 Jun 2017 Biomarkers information updated